Cargando…
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis due to the absence of complement regulators CD55 and CD59 on affected erythrocytes. Danicopan is a first-in-class oral proximal, complement alternative pathway factor D inhibitor. Therapeutic fa...
Autores principales: | Risitano, Antonio M., Kulasekararaj, Austin G., Lee, Jong Wook, Maciejewski, Jaroslaw P., Notaro, Rosario, Brodsky, Robert, Huang, Mingjun, Geffner, Michael, Browett, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634185/ https://www.ncbi.nlm.nih.gov/pubmed/33121236 http://dx.doi.org/10.3324/haematol.2020.261826 |
Ejemplares similares
-
Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021) -
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin G., et al.
Publicado: (2022) -
P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO
por: Wook Lee, Jong, et al.
Publicado: (2023) -
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
por: Risitano, Antonio M., et al.
Publicado: (2019) -
Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)